First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
出版年份 2019 全文链接
标题
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
作者
关键词
-
出版物
Targeted Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-09
DOI
10.1007/s11523-019-00670-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Erdafitinib: First Global Approval
- (2019) Anthony Markham DRUGS
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic
- (2016) Nicola J. Stagg et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
- (2016) Young Kwang Chae et al. Oncotarget
- Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma
- (2016) Ryuma Tokunaga et al. Oncotarget
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract 1683: Pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic/toxicodynamic (TK/TD) modeling of preclinical data of FGFR2-ADC (BAY 1187982) to guide dosing in phase 1
- (2015) Sabine Wittemer-Rump et al. CANCER RESEARCH
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction
- (2015) Edward P. Carter et al. TRENDS IN CELL BIOLOGY
- Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA
- (2015) John A. Martignetti et al. NEOPLASIA
- Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer
- (2014) Yoko Matsuda et al. CANCER SCIENCE
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma
- (2014) RYUJI OHASHI et al. ONCOLOGY REPORTS
- The Next Generation of Antibody Drug Conjugates
- (2014) Fiona Mack et al. SEMINARS IN ONCOLOGY
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
- (2013) Brittany C Parker et al. JOURNAL OF PATHOLOGY
- FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells
- (2013) Sungeun Kim et al. PLoS One
- Serum D-Dimer Concentrations in Nephrotic Syndrome Track with Albuminuria, Not Estimated Glomerular Filtration Rate
- (2012) D.J. Sexton et al. AMERICAN JOURNAL OF NEPHROLOGY
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fibroblast growth factors and their receptors in cancer
- (2011) Jørgen Wesche et al. BIOCHEMICAL JOURNAL
- Overexpressed fibroblast growth factor receptor 2 in the invasive front of colorectal cancer: A potential therapeutic target in colorectal cancer
- (2011) Yoko Matsuda et al. CANCER LETTERS
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer
- (2008) S Nomura et al. BRITISH JOURNAL OF CANCER
- First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
- (2008) C Tibaldi et al. BRITISH JOURNAL OF CANCER
- High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients With Nephrotic Syndrome
- (2007) Bakhtawar K. Mahmoodi et al. CIRCULATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started